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Abstract
Background: The perinatal period carries the highest risk for stroke in childhood; however, the pathophysiology is
poorly understood and preventive, prognostic, and therapeutic strategies are not available. A new pathophysiological
model describes the development of neonatal arterial ischemic stroke (NAIS) as the combined result of prenatal
inflammation and hypoxic–ischemic insult. Neuroinflammation and a systemic inflammatory response are also
important features of NAIS. Identifying key players of the inflammatory system is in the limelight of current research.
Case presentation: We present four NAIS cases, in whom detailed analysis of intracellular and plasma cytokine levels
are available from the first month of life. All neonates were admitted with the initial diagnosis of hypoxic ischemic
encephalopathy (HIE); however, early MRI examination revealed NAIS. Blood samples were collected between 3 and
6 h of life, at 24 h, 72 h, 1 week, and 1 month of life. Peripheral blood mononuclear cells were assessed with flow
cytometry and plasma cytokine levels were measured. Pooled data from the cohort of four NAIS patients were
compared to infants with HIE.
At 6 and 72 h of age, the prevalence of IL10+ CD8+ lymphocytes remained lower in NAIS. At 6 h, CD8+ lymphocytes
in NAIS produced more IL-17. At 72 h, CD8+ cells produced more IL-6 in severe HIE than in NAIS, but IL-6 production
remained elevated in CD8 cells at 1 month in NAIS, while it decreased in HIE. At 1 week, the prevalence of
TGF-β + lymphocytes prone to enter the CNS was elevated in NAIS. On the other hand, by 1 month of age,
the prevalence of TGF-β + CD4+ lymphocytes decreased in NAIS compared to HIE. At 72 h, we found elevated plasma
levels of IL-5, MCP-1, and IL-17 in NAIS. By 1 month, plasma levels of IL-4, IL-12, and IL-17 decreased in NAIS but
remained elevated in HIE.
Conclusions: Differences in the cytokine network are present between NAIS and HIE. CD8 lymphocytes appear to shift
towards the pro-inflammatory direction in NAIS. The inflammatory response appears to be more pronounced at 72 h
in NAIS but decreases faster, reaching lower plasma levels of inflammatory markers at 1 month.
Keywords: Neonatal arterial ischemic stroke, Hypoxic ischemic encephalopathy, Inflammatory response, Cytokine
network, T lymphocytes
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Background
The perinatal period carries the highest risk for stroke in
the entire childhood, with almost similar incidence to
that in the elderly population. “Perinatal stroke” is a
broad term defining a group of heterogeneous condi-
tions characterized by the focal disruption of cerebral
blood flow, of which neonatal arterial ischemic stroke
(NAIS) is one of the most common subtypes, with an in-
cidence of 1/8000 live births. NAIS by definition is an
arterial ischemic stroke, with clinical symptoms occur-
ring in the neonatal period (within the first 28 days of
life) which are supported by radiological evidence [1, 2].
NAIS generally occurs in term neonates and presents a
major risk for life-long motor, cognitive, and/or behav-
ioral disabilities ranging from fine motor impairments to
unilateral cerebral palsy, which develops in around 20–
30% of affected neonates. Thus NAIS is a leading cause
of cerebral palsy [3].
Interestingly, in almost all cases of NAIS, the
intra-cranial arteries developing from the carotid arterial
tree are affected, i.e., the proximal parts of the anterior
cerebral artery (ACA), the middle cerebral artery
(MCA), and the posterior cerebral artery (PCA)—while
the basilar artery and the extra-cranial arteries are left
unaffected [4–6]. The area of the left MCA is the most
common localization of the ischemic lesion, resulting in
a higher incidence of right-sided congenital hemiplegia
[1]. The clinical presentation of NAIS is often subtle and
non-specific, the most frequent symptoms being sei-
zures, general hypotonia, lethargy, and poor feeding,
making the timely diagnosis of NAIS difficult [7]. Diag-
nosis of NAIS is often delayed, due to the prenatal onset
or absence of specific signs; therefore, the primary focus
regarding therapeutic interventions is focused on pre-
vention and post-insult anti-inflammatory mechanisms
[3]. Another challenge regarding the diagnosis of NAIS
is the fact that the risk factors and clinical signs of global
hypoxic-ischemic encephalopathy (HIE) due to perinatal
asphyxia show a significant overlap with NAIS and the
two often co-occur [7–9]. Differentiating between the
two syndromes is a complex question, some studies list
perinatal asphyxia as an independent risk factor for
NAIS [10], while neuroinflammation following ischemia
appears to be a common feature of the two.
The pathophysiology of NAIS is poorly understood,
and disease-specific preventive measures, prognostic fac-
tors, and therapeutic strategies are not available. The
risk factors of NAIS appear to be specific for the peri-
natal period and can be clearly distinguished from the
risk factors of stroke in older children or adults. Major
risk factors such as congenital heart disease or bacterial
meningitis can be held accountable for approximately
30% of NAIS occurrences; however, in most of the cases,
NAIS is thought to be multifactorial, and in 25–40% of
cases, no identifiable risk factor is present [11, 12]. Only
a few case-control studies have aimed to specify risk fac-
tors; however, the number of cases was relatively low
and there is little consistency in the observed maternal,
obstetric, and neonatal risk factors [7, 13, 14]. The only
independent risk factor, which appeared in all
case-control studies, was perinatal inflammation, while
genetic prothrombotic disorders were not found to be
associated with the frequency of NAIS [3].
According to the classic pathophysiological hypothesis,
most ischemic lesions are a result of thromboembolic
events, where the presumable source of the thrombi is
the placenta or the umbilical vessels [15]. While in some
instances this could be the case, this hypothesis does not
give a plausible explanation to why NAIS is almost ex-
clusively affecting the intracranial arterial territories de-
veloping from the carotid arterial tree, while the
incidence of basilary arterial or extracerebral infarcts is
negligible [15]. In addition, there is angiographic evi-
dence indicating a possibility of local arterial wall defects
and in situ thrombus generation [9, 16]. Based on these
findings, Giraud et al. proposed a different pathome-
chanism, where maternofetal inflammation induces focal
arteritis specific to the intracranial arteries developing
from the carotid arterial tree, which are susceptible to
NAIS [3]. Using a preclinical rat model of chorioamnio-
nitis, they were able to demonstrate that classic pro-
thrombotic stress applied alone to the MCA was not
enough to induce NAIS; however, when combined with
in utero exposure to inflammation-inducing agent (LPS),
the same stress leads to the classical symptoms of NAIS
and motor impairment. They also examined the walls of
arteries susceptible to NAIS and found that the constitu-
tive expression of certain pro-inflammatory cytokines,
i.e., TNF-α and IL-1β, was higher in the susceptible
intra-cerebral arteries compared to extra-cerebral arter-
ies. Furthermore, pups born from LPS-exposed dams de-
veloped a specific cerebral arteritis with increased
presence of inflammatory cells (macrophages) and ele-
vated levels of pro-inflammatory cytokines IL-1β,
TNF-α, and MCP-1 with increased IL-1/IL-1 receptor
antagonist (ra) ratio in NAIS susceptible arteries, but
not elsewhere. [5]
Based on preclinical findings, a new pathophysiological
hypothesis is being raised, which considers the complex
and bidirectional relationship of coagulation and inflam-
matory pathways [17]. It describes the development of
NAIS as the result of a multiple hit mechanism, originat-
ing from both perinatal inflammation and hypoxia–is-
chemia (HI) [3]. Giraud et al. have identified three major
risk factors, the combination of which could lead to
NAIS: (i) materno-fetal inflammation leading to focal ar-
teritis of arteries susceptible to NAIS, (ii) a window of
susceptibility in the development of the neonatal brain,
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and (iii) the physiological pro-coagulatory state of the
perinatal period aggravated by the inflammatory re-
sponse [5]. Prenatal exposure to inflammation appears
to sensitize the brain for postnatal HI injury [18–20].
The inflammation could be of maternal, placental, or
fetal origin, which is in line with the proposed risk fac-
tors of NAIS (preeclampsia, chorioamnionitis, maternal
fever, infection) [3, 10]. In addition, the initial hypoxic
insult—as is now commonly recognized—is followed by
a generalized neuroinflammatory response. The initial
hypoxic insult leads to primary energy failure, necrosis,
subsequent glutamate release, oxidative stress, and as a
result excitotoxicity and widespread necrosis and
necroptosis within the first 6 h of the insult [21–23].
Neural tissue damage could be aggravated by previous
sensitization due to inflammation, which could lead to
increased oxidative stress and an increased production
of pro-inflammatory cytokines [19, 24–28]. The second
phase of neuroinflammation occurs from 24 until 72 h
after the initial HI insult and is characterized by the pro-
duction of inflammatory cytokines, the migration of leu-
kocytes into the brain tissue, and consequent apoptosis.
By identifying the key players of the neuroinflammatory
and apoptotic pathways, this second phase could be an
important time for targeted intervention [3, 29, 30]. In-
flammatory cells can be detected for weeks or even
months following the HI insult [31], and this sustained
inflammatory status can be considered the tertiary, la-
tent phase of the inflammatory response, which could
also be important regarding neurological outcome.
The primary aim of current research in the field of
perinatal stroke is to gain a better understanding of the
pathomechanism of the disease with specific regard to
the activation of the inflammatory pathway that could
present a possibility for more specific diagnosis, inter-
vention, and even prevention [3]. Human experimental
data on inflammatory markers is scarce; one
case-control study is available, where they aimed to de-
scribe the levels of different cytokines in the plasma of
NAIS patients. Elevated levels of TNF-α, IL-2, IL-6, and
IL-8 were observed 6 months following acute ischemic
stroke (AIS) compared to healthy controls. However, no
differences were observed in soluble endothelial protein
C receptor (sEPCR), IL-11, and FVIII median levels [32].
The limitation of this study is that they included both
neonatal and pediatric stroke cases (from birth until
18 years of age), which are now viewed as clinically dis-
tinct syndromes. These results indicate that an ongoing
inflammation could be observed up to 6 months follow-
ing AIS; however, no information is available regarding
the acute phase of NAIS.
The pivotal role of inflammatory pathways in ischemic
brain injury is supported by recent years’ research data.
T lymphocytes appear to play a central role in ischemic
infarct development; they appear in the brain tissue
within hours of the hypoxic insult and can be detected
for up to a month after the injury. T cell deficiency has
been shown to result in smaller infarct size and im-
proved neurological outcome in murine models [33, 34].
Several cytokines have been connected to acute ischemic
stroke in adults. Pro-inflammatory cytokines IL-1β, IL-8,
MCP-1, TNF-α, and IFN-γ appear to exacerbate cerebral
injury in adults, whereas anti-inflammatory cytokines
such as TGF-β and IL-10 appear to be neuroprotective
[35–37]. Although the immune system of neonates
shows many differences compared to adults, the inflam-
matory network appears to play a similarly critical role
in ischemic brain injury; therefore, it is reasonable to
hypothesize that the same cytokines might also influence
the course of neuroinflammation in the neonatal brain.
In this paper, we present four NAIS cases, in whom
detailed analysis of intracellular and plasma cytokine
levels are available from immediately after birth until the
first month of age. To our knowledge, no such informa-
tion is available in humans in NAIS; therefore, the data




All neonates were admitted to the regional cooling cen-
ter with the initial diagnosis of HIE, requiring thera-
peutic hypothermia. Eligibility for cooling was assessed
according to the TOBY criteria [38], and hypothermia
was initiated between 1 and 5 h of life. Rectal
temperature was maintained between 33 and 34 °C for
the 72-h intervention period. Clinical or culture-proven
sepsis was not detected in any of the infants. All infants
received regular preventive intravenous antibiotics, i.e.,
ampicillin and gentamicin during the hypothermic treat-
ment. MRI data were interpreted by radiologists who
were blinded to the clinical status of the neonates, based
on criteria defined by Rutherford et al. [39, 40].
A total of 33 term neonates were enrolled with written
parental consent in a study focusing on inflammatory
changes in HIE (approved by the Hungarian Medical Re-
search Council (TUKEB 6578-0/2011-EKU)). Four in-
fants were diagnosed with NAIS after their MRI scans
were completed. One infant was excluded due to sus-
pected metabolic disease. In the HIE group, data from
28 neonates were analyzed and divided into two groups
based on the severity of the hypoxic-ischemic encephal-
opathy. The groups were determined based on the initial
amplitude-integrated EEG (aEEG) recordings and the re-
covery time during monitoring [37] together with the
MRI scans, which were performed within the first week
of life. The severe group (n = 11) was formed of new-
borns with moderate-to-severe HIE signs on the MRI
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scan AND burst-suppression or continuous extremely
low voltage or flat tracing background activity on aEEG
OR normalization of aEEG after the 48th hour of life or
never, OR early death (< 28 days). Neonates that met
none of the above-listed criteria constituted the moder-
ate group (n = 17) (mild HIE signs on MRI scans AND
continuous or discontinuous normal voltage background
activity on aEEG OR normalization of aEEG activity be-
fore the 48th hour of life) [41]. Pooled data from the co-
hort of four NAIS patients were compared to infants
with HIE. In the severe HIE group, three infants de-
ceased before 1 month of age due to the severity of the
insult. Available data from these neonates were included
at the relevant time points within the severe group.
Therefore, 72-h, 1-week, and 1-month data were missing
in the case of two infants and 1-month data were miss-
ing from one infant. Clinical characteristics of infants
are summarized in Table 1.
Two milliliters of venous blood was collected between
3 and 6 h of life (at admission), as well as at 24 h, 72 h,
and 1 week of life, adjusted to blood sampling required
by clinical care. A further venous blood sample was ob-
tained at 1 month of age during a routine outpatient
follow-up appointment.
Flow cytometry
Plasma was separated from peripheral blood samples by
centrifugation. Plasma samples were aliquoted and im-
mediately frozen and stored at − 80 °C for later deter-
mination of cytokine concentrations.
Remaining cells were resuspended in RPMI (Roswell
Park Memorial Institute)-1640 medium (Sigma-Aldrich,
St. Louis, MO, USA). Cells were incubated with PMA
(phorbol 12-myristate 13-acetate) (50 ng/ml), ionomycin
(1 μg/ml), and BFA (Brefeldin A) (10 μg/ml) for 6 h at
37 °C to allow intracellular accumulation of cytokines.
For surface marker staining, samples were then incu-
bated with the following fluorochrome-conjugated
anti-human monoclonal antibodies: CD4 PE-Cy7 (phy-
coerythrin-cyanine 7) and CD8 APC-Cy7 (allophycocya-
nin-cyanine 7) (panel 1) or CD4 APC-Cy7 and CD49d
PerCP (peridinin-chlorophyll-protein) (panel 2), accord-
ing to the manufacturers’ instructions (all from BioLe-
gend, San Diego, CA, USA). Red blood cells were lysed
and PBMCs were permeabilized using FACSLysing and
FACSPermeabilizing solutions (BD Biosciences, San Jose,
CA, USA). Cells were washed and resuspended in PBS
(phosphate buffer saline) and divided into two equal ali-
quots and stained according to the manufacturers’ in-
structions for intracellular cytokines using the following
conjugated anti-human monoclonal antibodies or the
appropriate isotype controls: IL-6 PE (phycoerythrin),
IL-17A PerCP, IL-10 APC (allophycocyanin), and IFN-γ
FITC (fluorescein isothiocyanate) (for panel 1), or
TNF-α PE-Cy7, FoxP3 PE, TGF-β APC, and IL-1β FITC
(for panel 2), respectively (all from BioLegend). Follow-
ing labeling, cells were washed and resuspended in PBS
for flow cytometry analysis. Samples were analyzed im-
mediately on a FACSAria flow cytometer (BD Biosci-
ences) equipped with 488- and 633-nm excitation lasers.
Data were processed using the FACSDiVa software (BD
Biosciences). One hundred thousand cells were re-
corded. Evaluators of flow cytometry data were blinded
to the clinical status of the neonates.
Immunoassays
Plasma samples were stored at − 80 °C until analysis.
The plasma levels of the following cytokines, chemo-
kines, and growth factors were determined using
Bio-Plex Pro Assays (Bio-Rad Laboratories, Hercules,
CA, USA): IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10,
IL-12, IL-13, IL-17, IFN-γ, TNF-α, TGF-β, G-CSF,







Male gender (%) 10 (59%) 7 (64%) 2 (50%)
Birthweight (g) 3330 [2860–3605] 3000 [2490–3300] 3115 [2540–3885]
Gestational age (week) 39 [37–40] 38 [37–40] 39.5 [38.25–40]
No. of C-sections (%) 10 (59%) 8 (73%) 3 (75%)
Apgar at 1 min 3 [0.5–4.5] 1 [0–3] 4b [3–5]
Apgar at 5 min 6 [5–7] 2a, b [0–4] 5.5b [5, 6]
Apgar at 10 min 7 [5–8] 4a [1.75–5.25] 7b [6, 7]
Worst pH 7.03 [6.87–7.12] 6.86 [6.62–7.06] 6.94 [6.88–7.00]
Worst BD (mmol/L) 18.05 [16.65–21.28] 20.4 [19.38–23.5] 14b [14–17]
S100 (μg/L) 7.5 [2.33–28.85] 21.8 [3.8–30.0] 3.6b [1.88–18.35]
LDH (U/L) 2072 [1371–5274] 3335 [1879–5792] 1874 [1676–3187]
Data are presented as median and interquartile range; a = moderate vs severe HIE, p < 0.05; b = severe HIE vs NAIS, p < 0.05
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GM-CSF, MCP-1, MIP-1b, and VCAM. Bio-Plex Pro As-
says are immunoassays formatted on magnetic beads
that utilize principles similar to those of a sandwich
ELISA. Capture antibodies against the biomarker of
interest are covalently coupled to the beads. A biotinyl-
ated detection antibody creates the sandwich complex,
and the final detection complex is formed by the
addition of a streptavidin-phycoerythrin (SA-PE) conju-
gate, where PE serves as the fluorescent reporter. Reac-
tions are read using a Luminex-based reader.
Statistical analysis
Data are expressed as median and interquartile range.
Comparisons between sample populations were per-
formed with Mann-Whitney tests, as a test of normality
(performed according to Kolmogorov-Smirnoff ) indi-
cated non-normal distribution of data. Comparisons be-
tween the paired values (samples collected at different
time points) in the same population were made with
Friedman tests. p values less than 0.05 were considered
significant. Outliers were identified using Grubbs’ tests
and were excluded from analyses. Statistics were calcu-




The first patient was admitted following an emergency
cesarean section performed due to oligohydramnios and
fetal tachycardia on the 40th week of gestation. There
was no maternal history of chorioamnionitis. However,
the mother smoked during pregnancy. The amniotic
fluid was stained with thick meconium. The neonate was
born with an Apgar score of 5/6/7. She required intub-
ation and ventilation at birth. Her first capillary blood
gas showed lactic acidosis (pH 7.03, BE − 14 mmol/L,
lactate 12.4 mmol/L), and she became irritable and had
generalized increased muscle tone; thus, hypothermic
treatment was initiated. On the second day of life, she
presented with symptoms characteristic of pulmonary
hypertension, which resolved after 1 day of NO inhal-
ation and she was extubated on day 3 of life. Her early
neurodevelopmental examination showed mild central
hypotonia.
Cranial MRI with diffusion-weighted imaging was per-
formed on day 4 of life, which showed a distinct, 5 × 7 mm
area of ischemia with decreased diffusion in the left
thalamus and no evidence of bleeding. MR spectroscopy
showed a decrease in metabolites, correlating to minimal
hypoxic-ischemic encephalopathy.
Case 2
The second neonate was admitted following an emergency
cesarean section due to complete placental abruption on
the 39th week of gestation. He was born with an Apgar
score of 3/5/6/8. At the time of birth, he had a heartrate
of 80/min, had no respiratory effort, and was hypotonic
and pale. Following bag and mask ventilation, his heart-
rate normalized; however, only gasping could be observed,
so he was intubated. He later became irritable. His initial
blood gas showed severe metabolic acidosis (pH 6.99, BE
− 14). A chest X-ray was performed, which showed a
pneumothorax on the right side, which was drained and
hypothermic treatment was initiated. Due to severe
anemia and low blood pressure, he required blood trans-
fusion on two occasions and inotropic support for 6 days,
respectively. An early neurodevelopmental examination
indicated grossly abnormal central and peripheral tone
distribution.
Cranial MRI was performed on day 4 of life.
Diffusion-weighted imaging showed a large area of is-
chemia with decreased diffusion in the area of the left
middle cerebral artery, and several smaller lesions in the
area of the right middle cerebral artery. The area of the
left parietal cortex was blurred with hyperintensive sig-
nal subcortically. There were no signs of bleeding. TOF
MRI angiography showed marked irregularity and sig-
nificantly decreased blood flow in both, but particularly
in the left MCA. No MRI signs of hypoxic-ischemic en-
cephalopathy were present.
Case 3
The third neonate was born from an uncomplicated preg-
nancy on the 40th week of gestation, with an Apgar score
of 5/5. The neonate was hypotonic and had no spontaneous
breathing; therefore, she was intubated. The first gasping
breaths were observed at 15 min after birth, but she
remained generally hypotonic. The first blood gas showed
severe lactic acidosis (pH 6.89, BE − 18 mmol/L, lactate
15 mmol/L). Therapeutic hypothermia was commenced.
The initial aEEG recordings showed abnormal background
activity; however, this normalized after a few hours. The
early neurodevelopmental examination reported moderate
generalized hypotonia.
Cranial MRI was performed on day 3 of life.
Diffusion-weighted imaging showed a small (3 mm) ische-
mic lesion with decreased diffusion in the right thalamus.
No other signs of ischemia and bleeding or signs of hyp-
oxic ischemic encephalopathy could be observed.
Case 4
The fourth neonate was born from an uncomplicated
pregnancy on the 38th week of gestation by emergency
cesarean section due to imminent intrauterine asphyxia.
He was born with an Apgar score of 3/6/7. He was flaccid
with no signs of spontaneous breathing and a heart rate of
80/min. Following bag and mask ventilation, spontaneous
breathing was noted after 5 min, but the neonate
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remained hypotensive and areflexive. He was intubated
and hypothermic treatment was initiated. The aEEG re-
cording showed no signs of seizures. The initial blood gas
showed mixed acidosis (pH 6.875, BE − 14). The initial
neurodevelopmental examination demonstrated abnormal
central and peripheral tone distribution.
Cranial MRI was performed on day 1 of life.
Diffusion-weighted imaging showed decreased diffusion in-
dicating ischemia in the area of the right posterior cerebral
artery. Smaller lesions were present in the right thalamus
and the left parieto-occipital area. No signs of bleeding or
hypoxic ischemic encephalopathy were present.
Results
Intracellular cytokine data
At 6 and 72 h of age, the prevalence of CD8+ IL10+ lym-
phocytes remained lower in NAIS than in the severe HIE
group. Although the prevalence of CD8+ IL10+ lympho-
cytes remained consistently lower in NAIS, the difference
did not reach a significant level at the 24-h time point. On
the contrary, the prevalence of CD4+ IL-10+ was higher at
24 h in NAIS compared to moderate HIE. The prevalence
of IFN-γ +CD4+ cells showed an elevated tendency from
24 h in NAIS; however, this value did not reach signifi-
cance, which could be due to the small population. At
1 week, the prevalence of TGF-β + lymphocytes prone to
enter the CNS (CD4+ TGF-β +CD49d + lymphocytes) was
elevated in NAIS compared to both HIE groups, and also
compared to all other time points within the NAIS group
(Fig. 1). On the other hand, at 1 month of age, the preva-
lence of CD4+ TGF-β + lymphocytes decreased in NAIS
compared to HIE. Data are shown in Table 2.
At 6 h, the prevalence of CD8+ IL17+ lymphocytes
was higher in NAIS than in severe HIE and CD8 cells
expressed higher levels of IL-17 in NAIS than moderate
HIE. The level of IL-1β in CD4+ cells was highest at 6 h
and decreased significantly by 72 h within the NAIS
group. The mean fluorescence intensity (MFI) of IFN-γ
in CD4+ lymphocytes in NAIS was highest at 24 h and
decreased significantly by 72 h, when it reached a lower
level in NAIS than in either of the HIE groups. The MFI
of IL-6 in CD8+ cells was higher at 72 h in severe HIE
than in NAIS. Interestingly, by 1 month, the MFI of IL-6
in CD8+ decreased in both HIE groups and rose in
NAIS. Data are shown in Table 3.
We found no differences between NAIS and HIE in
the intracellular production of IL-1β and TNF-α in CD4
or CD8 cells; however, these cytokines appear to be im-
portant in differentiating between the mild and severe
form of HIE [41].
Plasma cytokine data
At 72 h, we found a marked inflammatory response in
NAIS, characterized by elevated plasma levels of IL-5,
IL-17, and MCP-1 compared to HIE. Plasma MCP-1
level was the highest at 72 h in NAIS. By 1 month, how-
ever, inflammatory response appears to be decreased in
NAIS compared with HIE, indicated by decreased
plasma levels of IL-4, IL-12, and IL-17 (Fig. 2). The level
of IL-4 was lower at 1 month than 72 h in NAIS.
We found no alterations in NAIS in the plasma level
of IL-1β, IL-2, IL-6, IL-7, IL8, IL-10, IL-13, IFN-γ,
TNF-α, TGF-β, G-CSF, GM-CSF, MIP-1b, and VCAM
when compared with HIE. Data are shown in Table 4.
Discussion
The contribution of T lymphocytes to ischemic brain in-
jury now appears to be clear, with CD8+ and CD4+ T
cells appearing in the CNS already a few hours after an
ischemic insult. The accumulation of T cells peaks
around 3–4 days following injury, and the inhibition of
T cell trafficking to the CNS decreases the deleterious
consequences of neuroinflammation [42, 43]. Data from
murine stroke models showed persisting presence of T
cells up to 7 weeks after the ischemic attack [44]. In our
NAIS patients, CD8 lymphocytes appear to show a
Fig. 1 Alterations of the prevalence of CD4+ TGF-β + CD49d + cells within the CD4+ population in the first month of life in moderate (n = 17)
and severe (n = 11) hypoxic-ischemic encephalopathy (HIE) and in NAIS (n = 4). Horizontal line: median, box: interquartile range, whisker: range.
p < 0.05 a vs 6 h, b vs 24 h, c vs 72 h
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different cytokine production pattern than HIE with a
more prominent pro-inflammatory response in NAIS. At
6 h, CD8 cells from NAIS patients produce higher levels
of pro-inflammatory IL-17 than those from neonates
with moderate HIE, and CD8+ IL17+ cells are more
prevalent in NAIS than in severe HIE. At 72 h, CD8 cells
of neonates with severe HIE produce higher levels of
pro-inflammatory IL-6 than CD8 cells of NAIS patients.
IL-6 is known to be an important factor in the early
phase of HIE, and this difference could reflect an aggra-
vated neuroinflammation in severe HIE. On the other
hand, IL-6 has also been described to have neurotrophic,
neuroregenerative, and anti-inflammatory properties
within the brain [45–48]. The alteration in intracellular
levels of IL-6 in CD8 cells becomes reversed by 1 month,
when it remains elevated in NAIS, whereas it decreases
in both HIE groups, indicating that a sustained level of
IL-6 might be present for a longer time in NAIS, which
is in line with literary data [32]. Therefore, IL-6 may
exert its neuroprotective effects over a longer period of
time in NAIS.
Plasma cytokine levels also indicate a difference between
NAIS and HIE, with a higher level of pro-inflammatory
response at 72 h in NAIS than in HIE. We found elevated
IL-5, IL-17, and MCP-1 levels at 72 in NAIS (see Table 3
for details.) MCP-1 was found to be elevated following
Table 2 Intracellular cytokines—cell prevalence data






IL-10+ CD8+ / CD8+ 6 h 2.75 (1.19–4.12) 4.19 (1.94–6.91) 1.10 (0.40–1.36)
b, p = 0.01
IL-10+ CD4+ / CD4+ 24 h 2.88 (1.56–7.03) 4.52 (3.02–6.59) 9.47 (5.10–20.68)
a, p = 0.03
IL-10+ CD8+ / CD8+ 72 h 3.51 (1.85–5.12) 5.30 (2.41–6.08) 1.39 (0.52–2.99)
b, p = 0.03
TGF-β + CD49d + CD4+ / CD4+ 1 week 10.54 (4.77–14.28) 10.0 (5.46–15.20) 38.00 (14.93–46.78)
a, p = 0.03; b, p = 0.05
TGF-β + CD4+ / CD4+ 1 month 3.51 (1.46–4.47) 3.54 (2.47–6.27) 1.30 (0.54–2.49)
b, p = 0.05
IL-17+ CD8+ / CD8+ 6 h 3.89 (5.26–14.40) 2.30 (1.73–4.49)
c, p = 0.02
5.04 (4.62–7.68)
b, p = 0.03
IFN-γ + CD4+ / CD4+ 72 h 6.40 (3.70–11.80) 6.17 (4.75–13.01) 17.50 (2.74–30.20)
IL-6+ CD8+ /CD8+ 72 h 4.37 (3.26–6.29) 5.63 (2.68–8.80) 8.87 (4.75–10.52)
IL-6+ CD8+ /CD8+ 1 month 4.02 (2.40–10.74) 3.70 (2.31–6.16) 4.47 (2.88–8.33)
The prevalence of T cells expressing various cytokines are shown as the percentage of the parent population
Table 3 Intracellular cytokines—mean fluorescence intensity (MFI) data






MFI IL-17 / CD8 6 h 1427 (661.5–2402) 1591 (1157–7047) 4855 (2618–8706)
a, p = 0.01
MFI IFN-γ / CD4 72 h 455 (149.5–770) 887 (495.5–1427) 42.25 (28.13–438.5)
a, p = 0.04;
b, p = 0.01
MFI IL-6 /CD8 72 h 701 (364.8–1441) 1073 (795–2017) 646.5 (188.7–736.3)
b, p = 0.03
MFI IL-6 / CD8 1 month 429 (101.7–617.0) 347 (83–491) 918.5 (638.3–1347)
a, p = 0.01;
b, p = 0.02
MFI IL-10 / CD8 6 h 1883 (512.5–5817) 1874 (1157–3415) 705 (280–3313)
MFI IL-10 / CD4 24 h 674.5 (177.8–2608) 1084 (203–1892) 666 (242.5–1063)
MFI IL-10 / CD8 72 h 2167 (1462–5964) 1505 (1055–3819) 443.5 (371–5977)
MFI TGF-β / CD4 1 week 4620 (2654–6647) 3129 (1238–5621) 3260 (1452–3680)
MFI TGF-β / CD4 1 month 811.5 (253–1740) 634 (259–1789) 330.5 (123–2283)
The intracellular level of certain cytokines in T cells is shown by the MFI of each cytokine. Data are expressed as median and interquartile range; a = moderate HIE
vs NAIS, p < 0.05; b = severe HIE vs NAIS, p < 0.05
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ischemic insult after in utero LPS exposure in a chorioam-
nionitis associated perinatal stroke murine model [5]. We
found an elevation in the level of MCP-1 at 72 h com-
pared to 6 h value in NAIS and to moderate HIE, which
supports previous data emphasizing the role of in utero
inflammation. Both the plasma levels of IL-17 and the
prevalence of pro-inflammatory Th17 and γδ T cells are
known to increase 1 week after adult acute ischemic
stroke [49] and decrease by 1 month. In line with these
findings, we found a higher level of IL-17 in the second
Fig. 2 Alterations of plasma cytokine levels in the first month of life in neonatal arterial ischemic stroke (n= 4). Horizontal line: median. p< 0.05 a vs 6 h,
b vs 24 h, c vs 72 h







IL-5 72 h 1.37 (0.00–4.69) 0.20 (0.00–0.46) 3.42 (1.42–6.35)
b, p = 0.01
IL-17 72 h 30.44 (26.65–51.62) 33.91 (29.16–48.02) 62.52 (51.62–645.7)
a, p = 0.04,
b, p = 0.05
MCP-1 72 h 251.9 (87.12–595.6) 678 (214–2311) 1090 (547.2–1254)
a, p = 0.03
IL-4 1 month 1.68 (0.84–2.54) 1.52 (0.84–2.44) 0.55 (0.22–0.89)
a, p = 0.04
b, p = 0.05
IL-12 1 month 18.11 (13.34–39.53) 21.52 (15.96–36.46) 11.74 (10.90–12.06)
a, p = 0.05
b, p = 0.05
IL-17 1 month 32.58 (22.02–51.92) 31.11 (19.50–74.08) 14.75 (10.49–15.85)
a, p = 0.02
b, p = 0.004
The plasma levels of cytokines are shown at different time points. Data are expressed as median and interquartile range; a = moderate HIE vs NAIS, p < 0.05;
b = severe HIE vs NAIS, p < 0.05
Bajnok et al. Journal of Neuroinflammation  (2018) 15:191 Page 8 of 11
phase (at 72 h) of neuroinflammation in NAIS compared
with HIE. By 1 month, however, the level of IL-17 de-
creased in NAIS, while it remained elevated in HIE. We
observed the same phenomenon with other cytokines
such as IL-4 and IL-12. Overall, the plasma levels of sev-
eral cytokines appear to decrease by 1 month of age in
NAIS and appears to remain at a higher level in HIE.
We also found alterations in the anti-inflammatory
pathways. IL-10 was thought to be primarily produced
by CD4+ lymphocytes; however, Trandem et al. demon-
strated in a murine model of virus encephalitis that the
most highly activated and cytotoxic CD8+ T cells are
also an important source of IL-10 at the peak of the in-
flammatory response. Their data suggests that CD8+
cells autoregulate their activation by IL-10 production
when the inflammatory response reaches a certain level
and that CD8-derived IL-10 has a primarily local effect
to prevent tissue damage. IL-10 expression by CD8 cells
rapidly decreased after 7 days, while CD4+ cells contin-
ued to express IL-10 for at least 42 days [50]. Our data
showed a significantly higher prevalence of IL-10+ CD8
+ lymphocytes in severe HIE than NAIS in the first 72 h
of life. IL10-producing CD8 cells were also more preva-
lent in mild HIE than in NAIS; however, the difference
was not significant. A lower prevalence of IL-10-producing
CD8 cells, which at the same time produce more of
pro-inflammatory cytokines such as IL-17, could lead to a
more prominent pro-inflammatory and cytolytic response
with decreased auto-regulatory IL-10 production in CD8
cells in NAIS in the first 72 h. Another interpretation could
be that the decreased level of IL-10 production by CD8+
cells reflects an in utero inflammatory response that de-
creases by the time of birth. Supporting this hypothesis, in
NAIS, we found elevated prevalence of IL10+ CD4+ lym-
phocytes, which are known to produce IL-10 for over a
month following the insult. Altogether, it appears that
IL-10 production is different in T cell subpopulations in
NAIS and HIE and the manipulation of the IL-10 pathway
could be interesting to explore from a neuroprotective
point of view.
The prevalence of TGF-β-producing CD4+ cells, the
majority of which are regulatory T (Treg) cells, was also
different in NAIS and HIE. TGF-β is one of the most
important cytokines regulating CNS repair. We found
increased CD49d expression in this population in NAIS
at 1 week compared to 24 h and both HIE groups,
reflecting a higher capacity of these cells to enter the
CNS. Meanwhile, the prevalence of the entire population
decreased by 1 month in NAIS compared to HIE. This
appears to be in line with plasma cytokine data, which
showed an increased inflammatory response in NAIS in
the second phase of neuroinflammation which could be
followed by an earlier reparative phase and a decreasing
inflammatory response by 1 month of age
Therapeutic hypothermia is currently the standard of
care for term neonates with HIE. There is substantial evi-
dence supporting the role of hypothermia in reducing mor-
tality and improving neurological outcome [51] in infants
with hypoxic ischemic encephalopathy. There is notable
evidence in animal focal cerebral ischemia models support-
ing the role of hypothermia in the reduction of infarct size
[52] and data suggesting that hypothermia might reduce
the risk of seizures after perinatal stroke and thus improve
outcome [53]. Therefore, there is intense discussion in the
scientific community about extending guidelines to include
new categories for therapeutic hypothermia such as pre-
term HIE and perinatal stroke; however, many issues re-
main to be addressed. Based on results from our previous
study, one of the mechanisms behind the neuroprotective
effect of hypothermia may be the reduction of systemic in-
flammatory response, seen in the reduced level of cytokines
such as IL-6 and IL-4 in HIE patients treated with
hypothermia compared to the normothermia group [54].
Therefore, it is likely that hypothermia may similarly re-
duce cytokine levels following NAIS.
The main limitation of these data is the small number of
cases; however, they could provide a hypothesis for future,
larger case-control studies. Another limitation is the lack
of healthy control population; however, due to ethical con-
siderations and the large number of blood sampling, enrol-
ling healthy neonates was not possible. We also saw a
notable variation in certain plasma cytokine levels, which is
likely a result of the relative instability of plasma cytokine
levels, which was the basis of primarily focusing on intra-
cellular cytokine production in the current study. The
value of the data from this study could lie in providing in-
centive for further clinical research on factors enabling dif-
ferentiation between the two disorders which often present
with similar symptoms at birth. Gaining a better under-
standing of the underlying pathophysiological factors is a
main aim at the current stage of research in NAIS.
Conclusions
CD8 lymphocytes appear to show a shift in the
pro-inflammatory direction in NAIS compared with HIE,
with elevated production of pro-inflammatory IL-17 at 6 h,
decreased auto-regulatory IL-10 production in the first
3 days, and elevated production of IL-6 at 1 month.
Altogether, the inflammatory response appears to be higher
at 72 h in NAIS than in HIE, but appears to decrease faster,
indicated by lower levels of inflammatory markers at 1 month
in NAIS than in HIE. Our data indicate similarities to obser-
vations in adult AIS and also support the hypothesis of an
ongoing in utero inflammation prior to NAIS. Further clin-
ical research in this area is pivotal, and a better understand-
ing of the pathophysiology could lead to identifying specific
factors to distinguish HIE from NAIS early and could open
up new pathways for prevention and individualized care.
Bajnok et al. Journal of Neuroinflammation  (2018) 15:191 Page 9 of 11
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